SCHEMBL5794550

SCHEMBL5794550

NC(=O)C(CC(F)F)NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 9/20 0.49
ADAMTS5 Q9UNA0 1/20 0.49
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
MMP9 P14780 5/20 0.47
CA2 P00918 4/20 0.47
CA1 P00915 3/20 0.47
MMP1 P03956 2/20 0.47
MMP13 P45452 2/20 0.47
MMP8 P22894 2/20 0.47
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
F2 P00734 1/20 0.44
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44
PRSS3 P35030 1/20 0.44
MMP3 P08254 1/20 0.44
MMP7 P09237 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1879215 0.86 MMP2 (0.53) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1871538 0.86 MMP2 (0.53) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1875644 0.83 MMP2 (0.49) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL310015 0.81 PSEN1 (0.48) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL12502549 0.81 PSEN1 (0.48) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1874090 0.80 MMP2 (0.49) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1875539 0.80 MMP2 (0.50) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1878137 0.80 MMP2 (0.49) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL5117214 0.78 MMP2 (0.74) MMP2ADAMTS5MMP9MMP1MMP13
SCHEMBL1872358 0.78 MMP2 (0.47) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144894-B2 Sulfonamide bicyclic compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2006-12-05 US disclosed
WO-2006034480-A2 SULFONAMIDE BICYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-03-30 WO disclosed
US-20060063799-A1 Sulfonamide bicyclic compounds BRISTOL-MYERS SQUIBB COMPANY 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063799-A1 Sulfonamide bicyclic compounds APP, BACE1, IAPP MMP2 2012/4885ADAMTS5 2310/4885SLC1A3 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.